olivLaw · US equity research
Precipio, Inc. PRPO
Laboratory Analytical Instruments · SIC 3826 · Vertical: Laboratory Analytical Instruments (SIC 3826)
Precipio is a cancer diagnostics biotechnology company that combines a clinical pathology laboratory with the development of its own tests for other laboratories. Net sales reached 24.0 million USD in fiscal 2025, and in the second quarter of 2026 the company reported a quarterly record, while it still carries substantial doubt about its ability to continue as a going concern.
At the close of 04 Nov 2026, Precipio, Inc. (PRPO) stock was 19.57 USD (+5.10% on the day), with market capitalisation 35.0 m USD, beta 0.56, 52-week range 17.79–32.37 USD. Latest reported quarter (Q2 2026): revenue of 7.0 m USD (+24.2% YoY), net income of -219.0 k USD (−395.9% YoY), diluted EPS -0.12 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 39.9
- weak (30–45)
- Bollinger (20, 2)
- 17.20 – 24.15
- in the lower half of the band · %B 0.34 · band width 33.6%
- SMA 50 / 200
- 23.86 / 24.91
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -1.48 / -1.43
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −18.5% | −1.1% | −17.4 pp | — |
| 3 months | −16.7% | −0.5% | −16.2 pp | — |
| 6 months | −34.7% | +4.4% | −39.1 pp | — |
| Year to date | −14.8% | +12.3% | −27.2 pp | — |
| 1 year | −2.5% | +13.5% | −16.0 pp | +15.7% |
| 3 years | +131.1% | +76.4% | +54.6 pp | −8.6% |
| 5 years | −58.2% | +63.7% | −121.9 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.2 m | 5.5 m | 4.9 m | 5.7 m | 6.8 m | 6.7 m | 6.7 m | 7.0 m |
| Cost of revenue | 2.9 m | 2.8 m | 2.8 m | 3.2 m | 3.8 m | 3.6 m | 4.0 m | 3.9 m |
| Gross profit | 2.3 m | 2.6 m | 2.1 m | 2.4 m | 3.0 m | 3.1 m | 2.7 m | 3.1 m |
| Operating income | -597.0 k | -336.0 k | -859.0 k | -824.0 k | -61.0 k | 542.0 k | -1.4 m | -599.0 k |
| Depreciation & amortisation | 299.0 k ≈ | 299.0 k | 324.0 k | 307.0 k ≈ | 307.0 k ≈ | 307.0 k | 281.0 k | 291.0 k ≈ |
| Pre-tax income | -626.0 k | -365.0 k | -884.0 k | 74.0 k | -79.0 k | 526.0 k | -1.4 m | -219.0 k |
| Net income | -626.0 k | -365.0 k | -884.0 k | 74.0 k | -79.0 k | 526.0 k | -1.4 m | -219.0 k |
| Diluted EPS | -0.42 | -0.24 ≈ | -0.59 | 0.05 | -0.05 | 0.30 ≈ | -0.81 | -0.12 |
| Operating cash flow | 41.0 k ≈ | 565.0 k | -44.0 k | 353.0 k ≈ | 10.0 k ≈ | 366.0 k | 64.0 k | 660.0 k ≈ |
| Capex | 109.0 k ≈ | 44.0 k | 138.0 k | 59.0 k ≈ | 54.0 k ≈ | 75.0 k | 50.0 k | 132.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.9 m | 3.1 m | 6.1 m | 8.8 m | 9.4 m | 15.2 m | 18.5 m | 24.0 m |
| Revenue YoY | +66.2% | +9.2% | +94.8% | +45.3% | +6.4% | +61.5% | +21.9% | +29.8% |
| Net income | -15.7 m | -13.2 m | -10.6 m | -8.5 m | -12.2 m | -5.9 m | -4.3 m | -363.0 k |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | -0.85 | -0.40 | -10.73 | -4.51 | -2.93 | -0.23 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -548.0% | -423.5% | -174.0% | -96.2% | -129.4% | -38.5% | -23.1% | -1.5% |
| Free cash flow | -6.9 m | -9.2 m | -7.6 m | -7.3 m | -8.0 m | -3.7 m | 216.0 k | 359.0 k |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 2.7 m USD
- Financial debt
- 77.0 k USD
- Net debt
- -2.6 m USD
- Equity
- 14.6 m USD
- Total assets
- 21.3 m USD
- Debt / equity
- 0.01x
- Current ratio
- 1.61x
- ROE
- -2.7%
- ROA
- -1.9%
- FCF margin
- 1.5%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 6.1 m | 8.8 m | 9.4 m | 15.2 m | 18.5 m | 24.0 m | SEC (XBRL)· 30 Mar 2026verified |
| Cost of revenue | 4.9 m | 6.5 m | 6.9 m | 9.2 m | 11.0 m | 13.3 m | SEC (XBRL)· 30 Mar 2026verified |
| Gross profit | 1.2 m | 2.4 m | 2.5 m | 6.0 m | 7.6 m | 10.7 m | SEC (XBRL)· 30 Mar 2026verified |
| Research & development | 1.2 m | 1.3 m | 1.7 m | 1.7 m | 1.3 m | 1.6 m | SEC (XBRL)· 30 Mar 2026verified |
| SG&A | 10.3 m | — | — | — | — | — | SEC (XBRL)· 29 Mar 2021verified |
| Operating income | -9.1 m | -9.6 m | -12.8 m | -7.6 m | -4.2 m | -1.2 m | SEC (XBRL)· 30 Mar 2026verified |
| Depreciation & amortisation | 1.1 m | 1.1 m | 1.2 m | 1.2 m | 1.2 m | 1.2 m | SEC (XBRL)· 30 Mar 2026verified |
| EBITDA | -8.1 m ≈ | -8.5 m ≈ | -11.6 m ≈ | -6.4 m ≈ | -3.0 m ≈ | 43.0 k ≈ | SEC (XBRL)· 30 Mar 2026derived |
| Pre-tax income | -10.6 m | -8.5 m | -12.2 m | -5.9 m | -4.3 m | -363.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | SEC (XBRL)· 30 Mar 2026verified |
| Net income | -10.6 m | -8.5 m | -12.2 m | -5.9 m | -4.3 m | -363.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Diluted EPS | -0.85 | -0.40 | -10.73 | -4.51 | -2.93 | -0.23 | SEC (XBRL)· 30 Mar 2026verified |
| Weighted average diluted shares | 16.5 m | 21.1 m | 1.1 m | 1.3 m | 1.5 m | 1.6 m | SEC (XBRL)· 30 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 2.7 m | 11.7 m | 3.4 m | 1.5 m | 1.4 m | 2.7 m | SEC (XBRL)· 30 Mar 2026verified |
| Receivables | 874.0 k | 697.0 k | 1.0 m | 1.3 m | 799.0 k | 2.0 m | SEC (XBRL)· 30 Mar 2026verified |
| Inventories | 350.0 k | 564.0 k | 708.0 k | 384.0 k | 724.0 k | 935.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Current assets | 4.2 m | 13.5 m | 5.7 m | 3.7 m | 3.5 m | 6.0 m | SEC (XBRL)· 30 Mar 2026verified |
| Property, plant & equipment, net | 277.0 k | 836.0 k | 877.0 k | 739.0 k | 719.0 k | 729.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Intangibles (excl. goodwill) | 15.7 m | 14.7 m | 13.8 m | 12.8 m | 11.9 m | 10.9 m | SEC (XBRL)· 30 Mar 2026verified |
| Total assets | 20.7 m | 30.4 m | 21.5 m | 18.1 m | 17.0 m | 21.3 m | SEC (XBRL)· 30 Mar 2026verified |
| Accounts payable | 1.7 m | 1.9 m | 2.0 m | 622.0 k | 618.0 k | 1.1 m | SEC (XBRL)· 30 Mar 2026verified |
| Short-term debt | 648.0 k | 26.0 k | 255.0 k | 235.0 k | 297.0 k | 30.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Long-term debt | 362.0 k | 160.0 k | 134.0 k | 106.0 k | 77.0 k | 47.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Current liabilities | 4.7 m | 4.2 m | 4.4 m | 3.1 m | 4.3 m | 3.8 m | SEC (XBRL)· 30 Mar 2026verified |
| Total liabilities | 6.6 m | 5.8 m | 5.1 m | 3.7 m | 4.9 m | 6.8 m | SEC (XBRL)· 30 Mar 2026verified |
| Equity | 14.2 m | 24.6 m | 16.4 m | 14.4 m | 12.1 m | 14.6 m | SEC (XBRL)· 30 Mar 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -7.4 m | -6.6 m | -7.7 m | -3.6 m | 439.0 k | 685.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Capex | 151.0 k | 682.0 k | 277.0 k | 126.0 k | 223.0 k | 326.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Free cash flow | -7.6 m ≈ | -7.3 m ≈ | -8.0 m ≈ | -3.7 m ≈ | 216.0 k ≈ | 359.0 k ≈ | SEC (XBRL)· 30 Mar 2026derived |
| Investing cash flow | -96.0 k | -682.0 k | -277.0 k | -126.0 k | -223.0 k | -326.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Financing cash flow | 9.3 m | 16.3 m | -225.0 k | 1.7 m | -329.0 k | 903.0 k | SEC (XBRL)· 30 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 37.5% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 35.0 m USD
Key indicators
Coverage and freshness
Score by group
38% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 37.5% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -11.2% | 14 (vs peers) | 28% |
| Net margin · Quality | -4.5% | 58 (vs peers) | 17% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 36.7% | 100 (on a fixed band) | 22% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 1.8x | 81 (on a fixed band) | 11% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 2.3% | 28 (on a fixed band) | 22% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial81/100 · 1/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality31/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial28/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
PRECIPIO, INC. (PRPO). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 24.0 m USD in 2025; YoY growth 29.8%; net margin -4.5%; ROE -9.0%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 37.5% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 36.7%
- Current ratio: 1.8x
What contradicts it
- ROIC: -11.2%
- FCF yield: 2.3%
Not assessed (insufficient data or a ratio without meaning): FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Laboratory Analytical Instruments (SIC 3826) · same industry (4-digit SIC) · compared with 20 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AAgilent Technologies, Inc. | 49.9 bn | 34.9 | 21.0% | 19.5% | +6.7% | +15% / +39% |
| WATWaters Corporation | 45.9 bn | 116.6 | 1.9% | 3.6% | +7.0% | +16% / +67% |
| MTDMettler-Toledo International Inc. | 34.5 bn | 38.8 | — | 21.9% | +4.0% | +17% / +58% |
| ILMNIllumina, Inc. | 34.3 bn | 38.8 | 32.4% | 19.7% | −0.7% | +72% / +128% |
| RVTYRevvity, Inc | 17.8 bn | 76.0 | 3.2% | 8.2% | +3.7% | +53% / +79% |
| AVTRAvantor, Inc. | 10.6 bn | 31.5 | 5.9% | 5.1% | −3.4% | +33% / −26% |
| BRKRBruker Corporation | 9.7 bn | — | -3.4% | -2.0% | +2.1% | +31% / −2% |
| TXG10x Genomics, Inc. | 8.6 bn | — | -9.4% | -12.2% | +5.2% | +259% / +55% |
| PACBPacific Biosciences of California, Inc. | 792.6 m | — | -929.3% | -82.5% | +3.9% | +10% / −70% |
| CTKBCytek Biosciences, Inc. | 769.0 m | — | -23.2% | -39.1% | +0.5% | +4% / −15% |
| MASS908 Devices Inc. | 457.6 m | — | -25.2% | -57.0% | +17.7% | +74% / +39% |
| NAUTNautilus Biotechnology, Inc. | 291.7 m | — | -41.0% | — | unavailable | +2% / −17% |
| QTRXQuanterix Corporation | 143.8 m | — | -46.5% | -80.2% | +1.1% | −58% / −87% |
| SEERSeer, Inc. | 94.1 m | — | -26.4% | -478.0% | +17.0% | −11% / +6% |
| HBIOHarvard Bioscience, Inc. | 39.2 m | — | -89.9% | -11.9% | −8.1% | +13% / −80% |
| PRPOPrecipio, Inc. | 35.0 m | — | -9.0% | -4.5% | +29.8% | −2% / +131% |
| EYPTEyePoint, Inc. | 34.1 m | — | -148.7% | -10,994.7% | −27.5% | −97% / −94% |
| BNGOBionano Genomics, Inc. | 14.0 m | — | -83.6% | -106.6% | −7.4% | −36% / −99% |
| ASTCAstrotech Corporation | 9.1 m | — | -75.4% | -1,580.2% | −8.7% | +41% / −44% |
| BIOBio-Rad Laboratories, Inc. | — | 10.0 | 14.3% | 39.5% | +0.7% | +17% / +25% |
| RPIDRapid Micro Biosystems, Inc. | — | — | -141.6% | -145.6% | +19.7% | −84% / −42% |
1- and 3-year price returns: for PRPO from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Precipio is a cancer diagnostics biotechnology company that combines a clinical pathology laboratory with the development of its own tests for other laboratories. Net sales reached 24.0 million USD in fiscal 2025, and in the second quarter of 2026 the company reported a quarterly record, while it still carries substantial doubt about its ability to continue as a going concern.
SWOT
Strengths
- Integrating clinical services with product development lowers research costs and gives access to patient samples that are hard to obtain from external sources.
- Revenue growth in fiscal 2025 and in the second quarter of 2026 points to steady demand for the company's services.
- The company built its cash position in the second quarter of 2026 without a new financing event, which suggests improving operations.
Weaknesses
- Accumulated losses are large, and the company says it can continue operating only if it achieves strong operating results or obtains additional financing.
- Dependence on a small number of customers exposes the company to major revenue and credit losses.
- Product revenue remains modest compared with service revenue, which limits diversification of the business.
Opportunities
- Extending the HemeScreen and IV-Cell panels to more laboratories could increase revenue in the products division.
- The US oncology market is large and growing, and international expansion could follow domestic success.
- If reimbursement for molecular tests improves, demand for the company's panels could increase.
Threats
- Large competitors have greater financial resources and may reach regulatory approvals sooner.
- Payer cost controls could reduce laboratory test prices and service margins.
- A natural disaster or termination of laboratory leases could seriously affect the company's operations.
Risks
- Going concernhigh
The auditor has expressed substantial doubt about the company's ability to continue as a going concern over the next twelve months. If financing is not available on acceptable terms, operations could be scaled back.
- Customer concentrationhigh
One customer accounted for a large share of revenue, and a few customers hold most of the receivables. Losing any of them could seriously affect results.
- Regulation and certificationmedium
Laboratories require ongoing CLIA certification, and products sold for research use could become subject to costly and uncertain marketing authorization.
- Litigation and dilutionmedium
The company may face costly litigation and may settle some cases by issuing equity, which could dilute existing shareholders.
- Share price volatility and listinglow
The share price may fluctuate significantly, and if Nasdaq listing requirements are not met, the securities could be delisted.
Investment thesis
What would need to be true (bull case)
- Steady revenue growth and a return to positive Adjusted EBITDA could show that the integrated model is starting to work. If case volume keeps rising, economies of scale could improve margins.
- A product platform with low-cost panels and access to clinical samples could become a real advantage if laboratories adopt it widely.
- The oncology market is large and growing, leaving room for product expansion if reimbursement remains favorable.
What would break the thesis
- Doubts about the going concern assumption remain significant, and reliance on additional financing could limit growth plans.
- Revenue is concentrated in services and a few large customers, while the products division remains small, which could slow diversification.
- Much larger competitors could capture the market if they offer similar technology at comparable cost.
What to watch
- Quarterly product revenue trends and adoption of the HemeScreen and IV-Cell panelsQ3 2026
- Update on the going concern assessment and any financing transactionsnext 10-Q
- Customer concentration and the evolution of receivables from the three largest customersnext 10-K
- Evolution of reimbursement and payer mix in the services division2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Precipio defines its mission as reducing diagnostic errors in hematologic cancer and operates a single segment made up of two complementary divisions. The pathology services division performs oncology tests for physicians and hospitals from its CLIA laboratories in New Haven and Omaha, and these clinical activities also serve as a validation environment for new products. The products division develops and sells its own test kits to other laboratories, and service revenue remains the dominant part of the business.
The company presents the integrated model as a competitive advantage, since the service laboratory works as a low-cost research unit and gives access to patient samples that are hard to obtain from external sources. It states that this structure shortens its time to market. The same sources indicate, however, that the benefits depend on laboratory adoption of its products, on reimbursement and on regulation.
The product portfolio includes HemeScreen, a set of RT-PCR based reagents for targeted genetic panels, and IV-Cell, a universal cell culture medium for the four hematopoietic lineages. The company holds pending US and European patent applications on its proprietary panels. Its market position remains narrow, and product revenue was only 2.7 million USD in fiscal 2025.
Segments
Pathology services division
This division generates most of the revenue, and in fiscal 2025 service revenue was 21.3 million USD. The number of cases processed rose 30% from the prior year, to 15,470 cases. The growth was driven by higher case volume rather than by changes in pricing.
Products division
The products division recorded revenue of 2.7 million USD in fiscal 2025, up 5% from the prior year. In the second quarter of 2026 product revenue reached 0.9 million USD, above the prior quarter. Growth depends on laboratory adoption and on regulatory and reimbursement factors.
Market context
The company defines its market as US oncology, where it competes as a commercial diagnostic laboratory and as a product supplier. According to the source, the total available oncology market could exceed 116 billion USD by 2034, with an estimated annual growth rate above 5%. The diagnostics product market could exceed 56 billion USD in annual revenue by 2030, and the company says international expansion would follow success in the US.
These market estimates come from the company and are not independently verified in these sources, so they should be read as assumptions. Market penetration depends on adoption by commercial laboratories and oncology practices, and large diagnostics companies have far greater resources.
Trends
- RT-PCR and targeted panelstailwind
The company argues that targeted panels on a single low-cost platform can reduce costs and turnaround time compared with NGS, which could attract laboratories. If laboratories adopt this model, the advantage could be significant.
- NCCN and WHO guidelines on genetic testingtailwind
Guidelines requiring specific genetic tests in the workup of hematologic cancers have made molecular testing a standard component. This development could support demand for the company's panels.
- Payer pressure on costsheadwind
Governmental payers and health plans have taken steps to control costs, and changes in payer mix could affect sales and profitability. If reimbursement falls, service margins could be affected.
- Regulation of tests and productsmixed
Products sold for research use or as laboratory developed tests could become subject to marketing authorization, a process that could be costly and uncertain. Regulation of artificial intelligence in diagnostics adds risk but also possible new products.
Competitive position
Competition in pathology services comes from two groups: oncology-focused laboratories such as NeoGenomics, GenPath Diagnostics and Inform Diagnostics, and large commercial laboratories such as LabCorp and Quest Diagnostics. In the liquid biopsy market, Foundation Medicine and Guardant Health also compete. In products, competitors are reagent manufacturers.
The sources show that many competitors have far greater financial and research resources than Precipio, and some may obtain regulatory approvals faster. This difference in scale could limit the company's ability to expand its market share.
- NeoGenomics LaboratoriesNEO
Oncology-focused laboratory offering services that directly compete for oncologists and hospital pathology departments.
- Laboratory Corporation of AmericaLH
Large commercial laboratory company with a broad range of tests, from simple chemistry to complex genetic testing.
- Quest DiagnosticsDGX
Large diagnostics company competing across a range of laboratory tests, including genetic testing.
- Foundation Medicine
Competitor in the liquid biopsy market with molecular cancer tests.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report29 Oct 2026Regulation FD disclosure · Financial statements and exhibits
- Current report14 Aug 2026Results of operations · Financial statements and exhibits
- Quarterly report14 Aug 2026
- Current report31 Jul 2026Regulation FD disclosure · Financial statements and exhibits
- Current report15 Jun 2026Shareholder vote
- Quarterly report14 May 2026
- Current report06 May 2026Regulation FD disclosure · Financial statements and exhibits
- Proxy statement28 Apr 2026
- Annual report30 Mar 2026
- Current report27 Feb 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Precipio, Inc. · 30 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Precipio, Inc. · 14 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Precipio, Inc. · 14 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.